The objectives of the Developmental Research Program (DRP) are to continue to renew our innovative scientific endeavors within the DF/HCC Lung Cancer SPORE and to fund efforts that will complement and enhance the overall quality of the DF/HCC Lung Cancer SPORE. The Developmental Research Program will fund both established and junior investigators as we have in the past. We will set aside $50,000 per year for the Developmental Research Program Awards from SPORE funds. The DF/HCC SPORE has an extensive track record of using institutional funds to support our Developmental Research Program. This will be supplemented with an additional $250,000 per year in institutional support as we have in the past. Three to 5 individuals will be awarded each year for as much as two years of funding. The second year of funding will be dependent on making sufficient progress on review by the Developmental Research Program. The award will facilitate the research and development of independence of basic biological science, translational science, and applied science investigators within the DF/HCC Lung Cancer SPORE program. Thus, candidates will be fellows, postdoctoral fellows, and faculty within the different training programs across the Harvard campus. Success in this Developmental Research Program Will be defined as the development of innovative translational science that will generate cancer-relevant interventions in patients with lung cancer or populations at risk for lung cancer. This program will use the infrastructure created by the Administration, Evaluation and Planning Core to: 1. Solicit applications and/or identify novel research projects in the area of lung cancer 2. Evaluate these projects for financial and core support 3. Fund innovative developmental research projects 4. Monitor progress on projects for potential transition into full project status 5. Evaluate the program's success in achieving its goals as well as overall SPORE objectives

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA090578-08
Application #
8112636
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
8
Fiscal Year
2010
Total Cost
$139,950
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
VanderLaan, Paul A; Rangachari, Deepa; Majid, Adnan et al. (2018) Tumor biomarker testing in non-small-cell lung cancer: A decade of change. Lung Cancer 116:90-95
Xu, Yinghui; Liu, Hongliang; Liu, Shun et al. (2018) Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer 143:2400-2408
Ji, Xuemei; Bossé, Yohan; Landi, Maria Teresa et al. (2018) Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nat Commun 9:3221
Guo, Yichen; Zhang, Ruyang; Shen, Sipeng et al. (2018) DNA Methylation of LRRC3B: A Biomarker for Survival of Early-Stage Non-Small Cell Lung Cancer Patients. Cancer Epidemiol Biomarkers Prev 27:1527-1535
Haines, Eric; Chen, Ting; Kommajosyula, Naveen et al. (2018) Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in KRAS-mutant non-small cell lung cancer. Oncotarget 9:31572-31589
Wang, Zhaoxi; Wei, Yongyue; Zhang, Ruyang et al. (2018) Multi-Omics Analysis Reveals a HIF Network and Hub Gene EPAS1 Associated with Lung Adenocarcinoma. EBioMedicine 32:93-101
Torous, Vanda F; Rangachari, Deepa; Gallant, Benjamin P et al. (2018) PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option? J Am Soc Cytopathol 7:133-141
Ferreiro-Iglesias, Aida; Lesseur, Corina; McKay, James et al. (2018) Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity. Nat Commun 9:3927
Sofer, Tamar; Schifano, Elizabeth D; Christiani, David C et al. (2017) Weighted pseudolikelihood for SNP set analysis with multiple secondary outcomes in case-control genetic association studies. Biometrics 73:1210-1220
Rangachari, Deepa; Le, Xiuning; Shea, Meghan et al. (2017) Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy. J Thorac Oncol 12:e175-e177

Showing the most recent 10 out of 263 publications